Intra-Cellular Therapies Stock Price and Value Analysis

Intra-Cellular Therapies (NasdaqGS:ITCI) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Intra-Cellular Therapies to reach your target.

Target type

ITCI Free Cash Flow Trend

Free Cash Flow trendline for ITCI
Free Cash Flow trendline for Intra-Cellular Therapies

Hmm, we can't give any reliable projection for Intra-Cellular Therapies's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the ITCI Numbers

ITCI Price
(Intra-Cellular Therapies stock price per share)
$0.00
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 52%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Intra-Cellular Therapies's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2024-12-05 Mates Sharon (Chairman and CEO) Sell 1,534 $84.69
2024-12-05 Mates Sharon (Chairman and CEO) Sell 50,163 $84.06
2024-12-04 Mates Sharon (Chairman and CEO) Sell 27,667 $85.62
2024-12-04 Mates Sharon (Chairman and CEO) Sell 23,333 $86.00
2024-11-13 Halstead Michael (President) Sell 13,371 $88.17
2024-11-13 Halstead Michael (President) Sell 5,343 $88.92
2024-11-12 Halstead Michael (President) Sell 1,648 $90.89
2024-11-12 Halstead Michael (President) Sell 6,116 $89.63
2024-11-12 Halstead Michael (President) Sell 15,105 $88.72
2024-08-30 Mates Sharon (Chairman and CEO) Sell 28,203 $72.73

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Net income was negative in all 13 fiscal years from 2012 to 2024, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$1,542 million over those years, against net income of -$1,678 million.

In 2024, net income was -$74.7 million and operating cash flow was -$73.2 million, so no ratio is shown for that year.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2012 -16.6 -18.9 0 n/a
2013 -26.9 -22.6 0 n/a
2014 -30.7 -22.8 0 n/a
2015 -105 -102 0.9 n/a
2016 -116 -91.3 0 n/a
2017 -97.8 -80.5 0.7 n/a
2018 -155 -118 0.4 n/a
2019 -148 -128 0.7 n/a
2020 -227 -230 0.3 n/a
2021 -284 -260 0.3 n/a
2022 -256 -270 0.8 n/a
2023 -140 -124 0.3 n/a
2024 -74.7 -73.2 0.3 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3.1 million in 2012 and $681 million in 2024, a compound annual growth rate of 56.7% over 12 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 46.6% from 2023 to 2024.

Our estimated free cash flow was -$73.6 million in 2024, a negative margin of 10.8% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 607.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2012 3.1 -18.9 -607.5%
2013 2.7 -22.6 -826.7%
2014 0.6 -22.8 -3955.5%
2015 0.1 -103 -112206.2%
2016 0.3 -91.5 -27655.1%
2017 0.2 -80.8 -32878.5%
2019 0.1 -129 -212047.2%
2020 22.8 -230 -1010.4%
2021 83.8 -260 -310.3%
2022 250 -271 -108.1%
2023 464 -125 -26.8%
2024 681 -73.6 -10.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2024, cash and equivalents were $307 million against total liabilities of $218 million, or 140.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 16.0% of total assets in 2024, compared with 14.3% in 2012, an increase of 1.7 percentage points.

Stockholders equity was $1,148 million in 2024, compared with $17 million in 2012, a rise of 6662.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -8.6% in 2024. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2012 19.8 15.6 2.8 17
2013 38.4 35.2 6.8 31.6
2014 131 61.3 10.6 121
2015 484 47.2 7.9 476
2016 389 48.6 13.4 376
2017 471 37.8 17 454
2018 357 54.9 39.5 318
2019 251 108 56.2 195
2020 717 60 60.5 657
2021 490 92.4 72 418
2022 755 149 98.7 656
2023 728 148 137 591
2024 1,367 307 218 1,148

Price Versus Our Estimated Value

We do not estimate a fair value for Intra-Cellular Therapies while its free cash flow growth is not positive, so there is no value comparison here.

Free cash flow was negative in every one of the 13 fiscal years we have for Intra-Cellular Therapies under its current filer.

Free cash flow is volatile from year to year, with a variability measure of 52%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Dividends are not in our data for Intra-Cellular Therapies.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Intra-Cellular Therapies, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Intra-Cellular Therapies (ITCI) - - - - -
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1567514.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 13 of the 13 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2024
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ITCI annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ITCI

Does Intra-Cellular Therapies have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ITCI

This example shows how we apply the Trendshare checklist to ITCI: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.